Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Viking Therapeutics Inc. (VKTX)

NASDAQ: VKTX · Pharmaceutical Preparations · San Diego, CA

Our rating: Positive

Positive reaffirmed at $27.28, moderate conviction, October 30, 2026.

Breaks if: The Positive call flips to Cautious immediately if VK2735's pivotal Phase 3 obesity trial misses its primary weight-loss endpoint — that outcome removes the thesis at its root, not just its timing. The call also weakens to Cautious if net cash runway falls below six quarters without a partnership payment or equity raise to cover it, given the current $279M annual cash consumption. On the other side, a pivotal readout showing weight loss clearly ahead of the Phase 2 baseline, or a major-pharma licensing deal with an upfront payment above $500M, would push the call toward Conviction.

Key figures

Market value$3.2B
Revenue, last 12 months$0.00
Net income, last 12 months−$627M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.0%
Operating marginn/a
Return on equity−96.4%
Beta to the S&P 5001.55
Volatility, annualized78.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$0.00n/a$-1.55n/a
June 30, 2026$0.00n/a$-1.10n/a
March 31, 2026$0.00n/a$-1.37n/a
December 31, 2025$0.00n/a$-1.39n/a
September 30, 2025$0.00n/a$-0.81n/a
June 30, 2025$0.00n/a$-0.58n/a
March 31, 2025$0.00n/a$-0.41n/a
December 31, 2024$0.00n/a$-0.32n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

32 ledger entries and 31 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.